Antimicrobial Therapy for Legionnaire’s Disease: Antibiotic Stewardship Implications

• Cheston B. Cunha ^[1] ; Burke A. Cunha ^[2]
  1. [1] Brown University

     Brown University

     City of Providence, Estados Unidos

     
  2. [2] State University of New York

     State University of New York

     City of Albany, Estados Unidos

     
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 31, Nº. 1, 2017, págs. 179-191
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Legionnaire’s disease is a common cause of community-acquired pneumonia (CAP). Although no single clinical feature is diagnostic, if characteristic extrapulmonary findings are present a presumptive clinical syndromic diagnosis is possible. Depending on geographic location, season, and physician awareness, Legionnaire’s disease may be included in the differential diagnosis of CAP. Some antibiotics effective against Legionella sp are also effective in treating the typical bacterial causes of CAP. From an antimicrobial stewardship program (ASP) perspective, monotherapy is preferred to double-drug therapy. From an ASP and pharmacoeconomic standpoint, monotherapy with doxycycline or a respiratory quinolone provides optimal cost effective therapy.